0T6G.LSE Q32 Bio Inc.

Healthcare Biotechnology London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
-31.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0T6G.LSE undervalued?

Graham number

The Graham number of Q32 Bio Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Q32 Bio Inc. fundamental analysis

No fundamental analysis for Q32 Bio Inc. yet.

Q32 Bio Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Q32 Bio Inc.

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling me…

Full company profile